ARCHIVES

New Phase III Trial Reviews Approve 25%; Should Trialists Worry? Not Yet,

This article is from The Cancer Letter archive.

Vol. 33 No. 02 | January 19, 2007

Download PDF Visit The Full Archive

Related Articles

Coordination, Funding Lacking In National Cancer Program: Report

October 7, 1994

CMX001 Reduces Adenovirus Progression and Viremia

August 30, 2013

Bishop: Scientists Need Seat At NCI Executive Committee, More Voice In Decision Making

February 24, 1995

Bailer NEJM “Irresponsible, Purposely Misleading,” Ignored Facts, DeVita Tells NCA

May 23, 1986

Amgen Cancels Rilotumumab Trials in Gastric Cancer

December 26, 2014

DCPC Board Approves $40 Million In New Concepts, Including Three In Breast Cancer, One In Melanoma

October 12, 1984